239 related articles for article (PubMed ID: 18779052)
1. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.
Lisco A; Vanpouille C; Tchesnokov EP; Grivel JC; Biancotto A; Brichacek B; Elliott J; Fromentin E; Shattock R; Anton P; Gorelick R; Balzarini J; McGuigan C; Derudas M; Götte M; Schinazi RF; Margolis L
Cell Host Microbe; 2008 Sep; 4(3):260-270. PubMed ID: 18779052
[TBL] [Abstract][Full Text] [Related]
2. Coinfection alters the playing field: herpesviruses induce acyclovir to inhibit HIV.
Stapleton JT; Balfour HH
Cell Host Microbe; 2008 Sep; 4(3):194-5. PubMed ID: 18779044
[TBL] [Abstract][Full Text] [Related]
3. A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.
Vanpouille C; Lisco A; Derudas M; Saba E; Grivel JC; Brichacek B; Scrimieri F; Schinazi R; Schols D; McGuigan C; Balzarini J; Margolis L
J Infect Dis; 2010 Feb; 201(4):635-43. PubMed ID: 20085496
[TBL] [Abstract][Full Text] [Related]
4. Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
Derudas M; Vanpouille C; Carta D; Zicari S; Andrei G; Snoeck R; Brancale A; Margolis L; Balzarini J; McGuigan C
J Med Chem; 2017 Sep; 60(18):7876-7896. PubMed ID: 28829913
[TBL] [Abstract][Full Text] [Related]
5. Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.
Vanpouille C; Lisco A; Introini A; Grivel JC; Munawwar A; Merbah M; Schinazi RF; Derudas M; McGuigan C; Balzarini J; Margolis L
Antimicrob Agents Chemother; 2012 May; 56(5):2604-11. PubMed ID: 22314523
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
Saijo M; Yasuda Y; Yabe H; Kato S; Suzutani T; De Clercq E; Niikura M; Maeda A; Kurane I; Morikawa S
J Med Virol; 2002 Sep; 68(1):99-104. PubMed ID: 12210436
[TBL] [Abstract][Full Text] [Related]
7. A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity.
Balzarini J; Andrei G; Balestra E; Huskens D; Vanpouille C; Introini A; Zicari S; Liekens S; Snoeck R; Holý A; Perno CF; Margolis L; Schols D
PLoS Pathog; 2013; 9(7):e1003456. PubMed ID: 23935482
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase.
Tchesnokov EP; Obikhod A; Massud I; Lisco A; Vanpouille C; Brichacek B; Balzarini J; McGuigan C; Derudas M; Margolis L; Schinazi RF; Götte M
J Biol Chem; 2009 Aug; 284(32):21496-504. PubMed ID: 19509419
[TBL] [Abstract][Full Text] [Related]
9. Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.
Vanpouille C; Lisco A; Grivel JC; Bassit LC; Kauffman RC; Sanchez J; Schinazi RF; Lederman MM; Rodriguez B; Margolis L
Clin Infect Dis; 2015 Jun; 60(11):1708-14. PubMed ID: 25740794
[TBL] [Abstract][Full Text] [Related]
10. Acyclovir: a new use for an old drug.
Vanpouille C; Lisco A; Margolis L
Curr Opin Infect Dis; 2009 Dec; 22(6):583-7. PubMed ID: 19726982
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.
McMahon MA; Siliciano JD; Kohli RM; Siliciano RF
AIDS; 2010 Jan; 24(2):319-23. PubMed ID: 20009920
[TBL] [Abstract][Full Text] [Related]
12. The effect of gramicidin, a topical contraceptive and antimicrobial agent with anti-HIV activity, against herpes simplex viruses type 1 and 2 in vitro.
Bourinbaiar AS; Coleman CF
Arch Virol; 1997; 142(11):2225-35. PubMed ID: 9672588
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir.
Balzarini J; Haller-Meier F; De Clercq E; Meier C
Antivir Chem Chemother; 2001 Sep; 12(5):301-6. PubMed ID: 11900349
[TBL] [Abstract][Full Text] [Related]
14. The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition.
Derudas M; Carta D; Brancale A; Vanpouille C; Lisco A; Margolis L; Balzarini J; McGuigan C
J Med Chem; 2009 Sep; 52(17):5520-30. PubMed ID: 19645484
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
Callebaut C; Stepan G; Tian Y; Miller MD
Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
[TBL] [Abstract][Full Text] [Related]
16. Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme.
Diez-Torrubia A; Cabrera S; de Castro S; García-Aparicio C; Mulder G; De Meester I; Camarasa MJ; Balzarini J; Velázquez S
Eur J Med Chem; 2013; 70():456-68. PubMed ID: 24185376
[TBL] [Abstract][Full Text] [Related]
17. The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase.
Andrei G; Gillemot S; Topalis D; Snoeck R
J Infect Dis; 2018 Feb; 217(5):790-801. PubMed ID: 29186456
[TBL] [Abstract][Full Text] [Related]
18. Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro.
Zakirova NF; Shipitsyn AV; Jasko MV; Prokofjeva MM; Andronova VL; Galegov GA; Prassolov VS; Kochetkov SN
Bioorg Med Chem; 2012 Oct; 20(19):5802-9. PubMed ID: 22954898
[TBL] [Abstract][Full Text] [Related]
19. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
20. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
Meng Q; Hagemeier SR; Fingeroth JD; Gershburg E; Pagano JS; Kenney SC
J Virol; 2010 May; 84(9):4534-42. PubMed ID: 20181711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
